Table 2 Characterization of different NP formulations.

From: Development and Pre-Clinical Evaluation of Recombinant Human Myelin Basic Protein Nano Therapeutic Vaccine in Experimental Autoimmune Encephalomyelitis Mice Animal Model

Formula

EE ± SD (%)

Particle size Z-average± SD(nm)

PDI

Zeta potential± SD (mV)

F1

N/A

N/A

N/A

N/A

F2

25.6 ± 0.4

502 ± 18

0.147

−15.9 ± 7.0

F3

27.3 ± 0.4

520 ± 4

0.255

−14.8 ± 0.4

F4

30.5 ± 0.5

576 ± 6*

0.175

−17.6 ± 7.1

F5

22.0 ± 0.4

546 ± 18

0.148

−21.3 ± 0.1*

F6

25.9 ± 0.6

596 ± 25*

0.257

−5.4 ± 0.1*

F7

49.9 ± 0.9*

508 ± 21

0.315

−17.1 ± 5.6

F8

32.5 ±1.0*

208 ± 12*

0.189

−16.6 ± 0.4

F9

35.8 ±0.9*

388 ± 13*

0.260

−22.6 ± 0.1*

rhMBP

99.9±1.7@

295 ± 15@

0.374

−18.6 ± 0.7

  1. rhMBP: recombinant human myelin basic protein.
  2. Each value represents mean ± SD (n = 3).
  3. N/A is not applicable.
  4. *Significantly different from the corresponding value of F3 at P < 0.05.
  5. @Significantly different from the corresponding value of F8 at P < 0.05.
Back to article page